10.1038/s41591-022-02182-7 - Allogeneic BCMA-targeting CAR T cells...

This document has been corrected

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Published Online: 2023-01-23

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC

Authors: Arun Balakumaran•Eric Butz•Erin E. Karski•Faiz Anwer•Jeffrey V. Matous•Jose Carlos Cruz•Michaela Liedtke•Myles Dillon•Myo Htut•Olalekan O. Oluwole•Rajneesh Nath•Saurabh Chhabra•Shahbaz Malik•Shaji K. Kumar•Sham Mailankody•Surbhi Sidana•Wade Lovelace•Wendy Ying

This document has been corrected

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

10.1038/s41591-022-02182-7

Published Online: 2023-01-23

Journal: Nature Medicine

NOW

2023-03-17•Correction

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

10.1038/s41591-023-02306-7

* information provided by CrossRef

2023-03-17•Correction

10.1038/s41591-023-02306-7

* information provided by CrossRef

2023-01-23•Published

2023-03-17•Correction

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

10.1038/s41591-023-02306-7

* information provided by CrossRef

This document has been corrected

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

10.1038/s41591-022-02182-7

Published Online: 2023-01-23

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC